BDSX Biodesix

Biodesix to Participate in Upcoming Investor Conferences

Biodesix to Participate in Upcoming Investor Conferences

LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences:

22nd Annual Craig-Hallum Institutional Investor Conference

1x1 Meetings

Date: Wednesday, May 28, 2025

Location: Minneapolis, MN

45th Annual William Blair Growth Stock Conference

Presentation and 1x1 Meetings

Date and Time: Wednesday, June 4, 2025 at 9:20 AM CT

Location: Chicago, IL

The presentation will be webcast live and available for replay under “News & Events” in the Investors section of the Company's website at .

About Biodesix

Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit .

Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.

Contacts:

Media:

Natalie St. Denis



1-720-925-9285

Investors:

Chris Brinzey



1-339-970-2843



EN
21/05/2025

Underlying

BDSXBiodesix

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biodesix

 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Participate in Upcoming Investor Conferences

Biodesix to Participate in Upcoming Investor Conferences LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference 1x1 MeetingsDate: Wednesday, May 28, 2025 Location: Minneapolis, MN 45th Annual William Blair Growth Stock Conference Presentation and 1x1 Meetings Date and Time: Wednesday, June 4, 2025 at 9:20 AM CTLocation: Chicago, IL The presentation will be web...

15h / 50m 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces New Clinical and Economic Data for its Nodify Lung®...

Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2025 Annual Meeting in Montreal, Quebec and at the American Thoracic Society (ATS) 2025 International Conference in San Francisco, California. The presentation titled “Time to Diagnosis of Lung Cancer from Identification of a Pulmonary Nodule in the United States” w...

May 15, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award LOUISVILLE, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, is pleased to announce that it is a . The Top Workplaces program has an 18-year history of surveying and celebrating people-first organizations nationally and across 60 regional markets. This recognition is based solely on gathered through a third-party survey, administered by employee engagement technology partner, . The confidential survey uniquely measures the employee experience and its component themes, includi...

May 14, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix Announces First Quarter 2025 Results and Highlights

Biodesix Announces First Quarter 2025 Results and Highlights Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to a range of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., May 13, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the first quarter ended March 31, 2025. “Our quarter was highlighted by continued progres...

May 13, 2025 1 EN
 PRESS RELEASE
Free
BDSX BIODESIX

Biodesix to Report First Quarter 2025 Financial Results on May 13, 202...

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 LOUISVILLE, Colo., April 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the first quarter ended March 31, 2025 after the close of trading on Tuesday, May 13. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this . Analysts who wish to participate in the qu...

April 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch